Adoptive immunotherapy of cancer: a new approach for cancer treatment.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Adoptive immunotherapy of cancer: a new approach for cancer treatment.

Diss Abstr Int [B]; 54(6):2983 1993. Unique Identifier : AIDSLINE ICDB/94605782
Qin YC; Limburgs Universitair Centrum, Belgium

Abstract: The conventional treatments of cancer are surgery, chemotherapy and radiotherapy. However, the therapeutic efficacy of these treatments are still far from satisfactory in most cases. With the development of immunology and increasing understanding in tumor immunology, immunotherapy has moved onto the stage of cancer treatments. Tumor infiltrating lymphocytes (TIL) therapy, as an adoptive immunotherapy form, has showed effectiveness in treating established lung and liver metastases in animal models. In preliminary human trials, 55% of the melanoma patients have responded to the TIL therapy. Studies have demonstrated that TIL are heterogeneous containing mostly CD3+ T cells with various amounts of CD4+ and CD8+ subsets, CD19+ B cells, CD16+ NK cells and other mononucleocytes. Functional study of TIL revealed that most of the T cell lines/clones derived from human breast tumor and melanoma tissues were cytotoxic as evaluated in lectin-dependent cytotoxicity assays which allow the detection of cytolytic T cells with any antigen specificity. Only a small portion of cytolytic T cells possess autologous tumor cell specificity. Analysis of T cell receptor of TIL lines/clones regarding DNA gene rearrangement and V beta gene expression suggest that an oligoclonal expansion of T cells might be present in tumor sites in encountering tumor antigen(s) or tumor associated antigen(s). The therapeutic efficacy of TIL therapy may be enhanced by cloning autologous tumor-specific T cells from tumor infiltrating lymphocytes, or by genetic manipulation to introduce new functional features to the TIL. (Full text available from University Microfilms International, Ann Arbor, MI, as Order No. AAD93-28553)

Keywords: Clinical Trials Cytotoxicity, Immunologic CD4-CD8 Ratio Human *Immunotherapy, Adoptive Liver Neoplasms/SECONDARY/*THERAPY Lung Neoplasms/SECONDARY/*THERAPY Lymphocytes, Tumor-Infiltrating/IMMUNOLOGY Melanoma/IMMUNOLOGY/PATHOLOGY Neoplasms/*THERAPY THESIS
941230
M94C4342

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .